On December 13, 2018, Erik Ostrowski provided notice of his resignation as chief financial officer of
Summit Therapeutics plc (the Company). Mr. Ostrowskis resignation will become effective on December 28, 2018. The related U.K. announcement is attached hereto as Exhibit 99.1.
The Company will appoint a new chief financial officer in due course.
Forward-looking Statements
Any statements in this report
about the Companys future expectations, plans and prospects, including but not limited to, statements about its plans to appoint a new chief financial officer, the potential benefits and future operation of the BARDA or
CARB-X
contract, including any potential future payments thereunder, the clinical and preclinical development of the Companys product candidates, the therapeutic potential of the Companys product
candidates, the potential of the Discuva Platform, the potential commercialisation of the Companys product candidates, the sufficiency of the Companys cash resources, the timing of initiation, completion and availability of data from
clinical trials, the potential submission of applications for marketing approvals and other statements containing the words anticipate, believe, continue, could, estimate,
expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:
the ability of BARDA or
CARB-X
to terminate our contract for convenience at any time, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and
future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of
the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts, availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital
expenditure requirements and other factors discussed in the Risk Factors section of filings that the Company makes with the Securities and Exchange Commission, including the Companys Annual Report on Form
20-F
for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this
report represent the Companys views only as of the date of this report and should not be relied upon as representing the Companys views as of any subsequent date. The Company specifically disclaims any obligation to update any
forward-looking statements included in this report.
The information in this Report on Form
6-K,
including Exhibit
99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such a filing.